Paula Cipollone Sells 3,369 Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Paula Cipollone sold 3,369 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $7.45, for a total value of $25,099.05. Following the completion of the transaction, the insider now directly owns 290,193 shares in the company, valued at approximately $2,161,937.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paula Cipollone also recently made the following trade(s):

• On Monday, March 11th, Paula Cipollone sold 13,996 shares of LifeStance Health Group stock. The stock was sold at an average price of $6.93, for a total value of $96,992.28.

LifeStance Health Group Stock Down 1.3 %

NASDAQ:LFST opened at $6.05 on Friday. LifeStance Health Group, Inc. has a 1 year low of $4.74 and a 1 year high of $9.59. The business has a 50 day simple moving average of $6.55 and a 200-day simple moving average of $6.58. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.20.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.03). LifeStance Health Group had a negative net margin of 17.64% and a negative return on equity of 12.66%. The company had revenue of $280.60 million during the quarter, compared to the consensus estimate of $263.14 million. As a group, research analysts anticipate that LifeStance Health Group, Inc. will post -0.3 EPS for the current year.

Institutional Investors Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently modified their holdings of LFST. Price T Rowe Associates Inc. MD raised its position in LifeStance Health Group by 10.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,623 shares of the company’s stock valued at $102,000 after purchasing an additional 1,294 shares in the last quarter. Osaic Holdings Inc. raised its position in LifeStance Health Group by 6.1% during the 2nd quarter. Osaic Holdings Inc. now owns 23,141 shares of the company’s stock valued at $211,000 after purchasing an additional 1,333 shares in the last quarter. Invesco Ltd. raised its position in LifeStance Health Group by 13.2% during the 1st quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock valued at $170,000 after purchasing an additional 1,964 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of LifeStance Health Group by 56.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,575 shares of the company’s stock valued at $56,000 after acquiring an additional 2,016 shares during the period. Finally, Assetmark Inc. increased its holdings in shares of LifeStance Health Group by 21.6% in the 4th quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock valued at $93,000 after acquiring an additional 2,114 shares during the period. 85.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LFST has been the subject of several research analyst reports. Barclays increased their target price on LifeStance Health Group from $7.00 to $8.00 and gave the stock an “underweight” rating in a research report on Thursday, February 29th. Jefferies Financial Group increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Finally, The Goldman Sachs Group increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.60.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.